PCI Pharma Services (PCI) has unveiled an investment in a new state-of-the art clinical facility near Dublin, Ireland which will increase capabilities and capacity for its clinical services business as a part of its overall global network expansion strategy. On completion, the building will provide more than 75,000 square feet of space, serving as a key primary and secondary packaging, storage, logistics and distribution center. The expansion will take place over the coming months and will bring additional controlled room temperature and cold chain storage capabilities for PCI customers, as well as clinical packaging services.
 
This new investment will complement PCI’s already established footprint in Dublin, Ireland following the acquisition of Millmount Healthcare in 2017. The facility, which is licensed by HPRA, also offers clinical storage and distribution (S&D) for the shipment of Investigational Medicinal Products (IMP) to sites based both within the EU and globally. Additional services at the site include cold chain handling, packaging and storage capabilities for clinical and commercial products and serialization capability as well as a full analytical release testing laboratory. Since the acquisition establishing its presence in Ireland, PCI has debuted a state-of-the-art dedicated high containment packaging facility specializing in commercial primary and secondary packaging for all solid oral dose forms including specialized and high potent products.
 
“Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent,” said Salim Haffar, chief executive officer, PCI. “We are very pleased with our team’s progress in expanding our global footprint as we partner with our customers in the shared goal of improving patients’ lives.